CervoMed (CRVO) announced the appointment of David Quigley to its Board of Directors. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm’s Life Sciences and Private Equity practices. His appointment comes as CervoMed prepares for key milestones, including U.S. Food and Drug Administration feedback on the design of its planned Phase 3 trial in patients with dementia with Lewy bodies, expected during the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- Cervomed Inc. Advances Stroke Recovery Research with Promising Clinical Study
- Cervomed Inc.’s Promising Phase 2a Study on Neflamapimod for Aphasia
- CervoMed Releases Investor Presentation on Website
- CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating
- CervoMed price target raised to $20 from $16 at Roth Capital